These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 27198171)
1. Association of breed and histopathological grade in canine mast cell tumours. Mochizuki H; Motsinger-Reif A; Bettini C; Moroff S; Breen M Vet Comp Oncol; 2017 Sep; 15(3):829-839. PubMed ID: 27198171 [TBL] [Abstract][Full Text] [Related]
2. Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification. Śmiech A; Ślaska B; Łopuszyński W; Jasik A; Bochyńska D; Dąbrowski R Acta Vet Scand; 2018 Nov; 60(1):70. PubMed ID: 30390687 [TBL] [Abstract][Full Text] [Related]
3. Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours. Schlieben P; Meyer A; Weise C; Bondzio A; Einspanier R; Gruber AD; Klopfleisch R Vet J; 2012 Nov; 194(2):210-4. PubMed ID: 22578690 [TBL] [Abstract][Full Text] [Related]
4. Histologic grading of canine mast cell tumor: is 2 better than 3? Sabattini S; Scarpa F; Berlato D; Bettini G Vet Pathol; 2015 Jan; 52(1):70-3. PubMed ID: 24513799 [TBL] [Abstract][Full Text] [Related]
5. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours. Vozdova M; Kubickova S; Fictum P; Fröhlich J; Jelinek F; Rubes J Vet J; 2019 May; 247():71-74. PubMed ID: 30971355 [TBL] [Abstract][Full Text] [Related]
6. Use of neutrophil to lymphocyte ratio for predicting histopathological grade of canine mast cell tumours. Macfarlane MJ; Macfarlane LL; Scase T; Parkin T; Morris JS Vet Rec; 2016 Nov; 179(19):491. PubMed ID: 27650464 [TBL] [Abstract][Full Text] [Related]
7. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis. Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539 [TBL] [Abstract][Full Text] [Related]
8. Breed related odds ratio and anatomic distribution of canine mast cell tumours in Austria. Retrospective study of cases in the years 2000-2010. Leidinger EF; Freeman K; Kirtz G; Hooijberg EH; Sick K Tierarztl Prax Ausg K Kleintiere Heimtiere; 2014; 42(6):367-73. PubMed ID: 25418504 [TBL] [Abstract][Full Text] [Related]
9. An immunohistochemical study of vitamin D receptor expression in canine cutaneous mast cell tumours. Russell DS; Rassnick KM; Erb HN; Vaughan MM; McDonough SP J Comp Pathol; 2010; 143(2-3):223-6. PubMed ID: 20334872 [TBL] [Abstract][Full Text] [Related]
10. Retrospective outcome evaluation for dogs with surgically excised, solitary Kiupel high-grade, cutaneous mast cell tumours. Moore AS; Frimberger AE; Taylor D; Sullivan N Vet Comp Oncol; 2020 Sep; 18(3):402-408. PubMed ID: 31916687 [TBL] [Abstract][Full Text] [Related]
11. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours. Meyer A; Gruber AD; Klopfleisch R J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the global DNA methylation in canine mast cell tumour samples by immunostaining of 5-methyl cytosine. Morimoto CY; Tedardi MV; da Fonseca IIM; Kimura KC; Sanches DS; Epiphanio TF; de Francisco Strefezzi R; Dagli MLZ Vet Comp Oncol; 2017 Sep; 15(3):1014-1018. PubMed ID: 27140659 [TBL] [Abstract][Full Text] [Related]
13. Patient and tumour factors influencing canine mast cell tumour histological grade and mitotic index. Reynolds BD; Thomson MJ; O'Connell K; Morgan EJ; Gummow B Vet Comp Oncol; 2019 Sep; 17(3):338-344. PubMed ID: 30891882 [TBL] [Abstract][Full Text] [Related]
14. Comparison of serum tryptase as a diagnostic oncological marker in canine versus human mast cell neoplasms. De Vos S; Demeyere K; De Cock H; Devriendt N; Schwarzkopf I; Fortrie R; Roggeman T; Meyer E; De Spiegelaere W; de Rooster H Res Vet Sci; 2022 Dec; 151():90-95. PubMed ID: 35872552 [TBL] [Abstract][Full Text] [Related]
16. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours. Kiupel M; Webster JD; Miller RA; Kaneene JB J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909 [TBL] [Abstract][Full Text] [Related]
17. The treatment of canine mast cell tumours with electrochemotherapy with or without surgical excision. Lowe R; Gavazza A; Impellizeri JA; Soden DM; Lubas G Vet Comp Oncol; 2017 Sep; 15(3):775-784. PubMed ID: 27001443 [TBL] [Abstract][Full Text] [Related]
18. Widespread mismatch repair protein expression in canine cutaneous mast cell tumors. Munday JS; French AF; Gibson IR; Gwynne K Vet Pathol; 2009 Mar; 46(2):227-32. PubMed ID: 19261633 [TBL] [Abstract][Full Text] [Related]
19. Cutaneous MCTs: associations with spay/neuter status, breed, body size, and phylogenetic cluster. White CR; Hohenhaus AE; Kelsey J; Procter-Gray E J Am Anim Hosp Assoc; 2011; 47(3):210-6. PubMed ID: 21498594 [TBL] [Abstract][Full Text] [Related]
20. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours. Smrkovski OA; Essick L; Rohrbach BW; Legendre AM Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]